Overview

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The goals of this study is to determine if nelfinavir can target Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) in patients with certain cancers.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Treatments:
Nelfinavir